Research programme: AL amyloidosis therapeutics - BELLUS Health
Latest Information Update: 03 Mar 2015
At a glance
- Originator BELLUS Health
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyloid light-chain amyloidosis